|
rs747418061
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Resistance to activated protein C (APC resistance) due to the factor V mutation 506 Arg-->Gln (factor V Leiden) is the most prevalent inherited risk factor for venous thromboembolism.
|
8589213 |
1995 |
|
rs6025
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden).
|
9010145 |
1997 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We conclude that screening for the C677T mutation of the methylenetetrahydrofolate reductase gene should not be recommended in unselected patients with VT.
|
9217179 |
1997 |
|
rs6025
|
|
|
0.900 |
GeneticVariation |
BEFREE |
A single factor V gene G-A mutation (Arg506Gln) underlying activated protein C (APC) resistance is a common risk factor for venous thromboembolism.
|
9705241 |
1998 |
|
rs1183194405
|
|
|
0.020 |
GeneticVariation |
BEFREE |
To investigate the possible role of factor XIII Val34Leu in the pathogenesis of venous thromboembolism (VTE) and potential interactions with factor V Leiden (FV:Q506) and prothrombin G --> A 20210, we studied 221 patients with a history of VTE and 254 healthy controls.
|
9920839 |
1999 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Heterozygous and homozygous factor V G1691A, factor II G20210A, and homozygous MTHFR C677T were found to be independent risk factors for VTE, with odds ratios of 16.3, 3.6, and 2.1, respectively.
|
10073951 |
1999 |
|
rs1800562
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Risk of venous thromboembolism associated with the common hereditary haemochromatosis Hfe gene (C282Y) mutation.
|
10233369 |
1999 |
|
rs751377893
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation.
|
10365737 |
1999 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation.
|
10365737 |
1999 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Venous thromboembolism at a young age in a brother and sister with coinheritance of homozygous 20210A/A prothrombin mutation and heterozygous 1691G/A factor V Leiden mutation.
|
10456622 |
1999 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To clarify the contribution of C677T MTHFR mutation in arterial occlusive disease (AOD) or venous thromboembolism (VTE), we performed a case-controlled study including 160 cases with AOD and 180 cases with VTE attending our referral center and compared them with 200 matched healthy controls.
|
10477457 |
1999 |
|
rs552953108
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Because both factor V R506Q</span> and the HR2 haplotype are very frequent, the effect of their coinheritance on the risk of venous thromboembolism might represent a clinically relevant issue, and screening for HR2 in carriers of factor V R506Q should be considered.
|
10556190 |
1999 |
|
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Prothrombin 20210 G-->A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy.
|
10759281 |
2000 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Prothrombin 20210 G-->A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy.
|
10759281 |
2000 |
|
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The frequencies of Factor V G1691A (FVL), prothrombin (PT) G20210A, 5'10'methylenetetrahydrofolate reductase (MTHFR) C677T, and methionine synthase (MS) A2756G (four mutations associated with an increased risk of venous thromboembolism [VTE]) were determined in a sample of approximately 1500 New York State residents.
|
10963782 |
2000 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The frequencies of Factor V G1691A (FVL), prothrombin (PT) G20210A, 5'10'methylenetetrahydrofolate reductase (MTHFR) C677T, and methionine synthase (MS) A2756G (four mutations associated with an increased risk of venous thromboembolism [VTE]) were determined in a sample of approximately 1500 New York State residents.
|
10963782 |
2000 |
|
rs1805087
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The frequencies of Factor V G1691A (FVL), prothrombin (PT) G20210A, 5'10'methylenetetrahydrofolate reductase (MTHFR) C677T, and methionine synthase (MS) A2756G (four mutations associated with an increased risk of venous thromboembolism [VTE]) were determined in a sample of approximately 1500 New York State residents.
|
10963782 |
2000 |
|
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Genotyping for mutations that are possible causes of moderate hyperhomocysteinemia, such as the thermolabile variant (C677T) of methylenetetrahydrofolate reductase (MTHFR), does not seem useful to identify individuals at higher risk for venous thromboembolism.
|
11011848 |
2000 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Genotyping for mutations that are possible causes of moderate hyperhomocysteinemia, such as the thermolabile variant (C677T) of methylenetetrahydrofolate reductase (MTHFR), does not seem useful to identify individuals at higher risk for venous thromboembolism.
|
11011848 |
2000 |
|
rs899127658
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The coexistence of FV G1691A and elevated Lp(a) was significantly more prevalent among patients with VTE than in the control group (7% versus 0.8%; P <.001, OR 9.8, 95% CI, 2.4-40.7).
|
11071628 |
2000 |
|
rs1188383936
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study suggests that the homozygous C677T mutation in the MTHFR gene might be a risk factor of VTE in patients with spontaneous events and without other common genetic risk factors.
|
11124649 |
2000 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study suggests that the homozygous C677T mutation in the MTHFR gene might be a risk factor of VTE in patients with spontaneous events and without other common genetic risk factors.
|
11124649 |
2000 |
|
rs552953108
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The determination of the factor II: G20210A variant in index patients carrying a factor V: R506Q mutation and, if present, in family members may help to identify individuals who are at high risk for VTE.
|
11737249 |
2001 |
|
rs1217691063
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Fasting total homocysteine (tHcy) and the methylenetetrahydrofolate reductase (MTHFR) C677T mutation were evaluated in 91 patients with venous thromboembolism and without acquired thrombophilia, and in 91 age-matched and sex-matched controls.
|
11943942 |
2002 |
|
rs552953108
|
|
|
0.060 |
GeneticVariation |
BEFREE |
In non-oral contraceptive users the risk of venous thromboembolism was significantly increased in carriers of R506Q but not in those with the G20210A mutation.
|
12069454 |
2002 |